PMID- 31998006
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220412
IS  - 1642-395X (Print)
IS  - 2299-0046 (Electronic)
IS  - 1642-395X (Linking)
VI  - 36
IP  - 6
DP  - 2019 Dec
TI  - Efficacy and safety of topical calcineurin inhibitors for the treatment of atopic 
      dermatitis: meta-analysis of randomized clinical trials.
PG  - 752-759
LID - 10.5114/ada.2019.91425 [doi]
AB  - INTRODUCTION: Calcineurin inhibitors, novel topical immunomodulators, may 
      constitute a superior alternative for glucocorticosteroids in atopic dermatitis 
      (AD) topical treatment. AIM: Determination of efficacy and safety of each topical 
      calcineurin inhibitor (TCI) formulation, 0.3% or 0.1% tacrolimus and 1% 
      pimecrolimus, for the treatment of moderate to severe AD in comparison with 
      glucocorticosteroids. MATERIAL AND METHODS: Cochrane Central Register of 
      Controlled Trials (CENTRAL), MEDLINE, EMBASE, GREAT database, trials registers 
      and reference lists were searched up to February 2018. Randomised controlled 
      trials of TCI, compared to corticosteroids (TCS), reporting efficacy or safety 
      outcomes were selected. Quality of trials and evidence of each outcome were 
      evaluated according to Cochrane Collaboration recommendations and tools. The 
      primary outcomes were physician's global assessment of improvement and occurrence 
      of adverse events (AEs). RESULTS: Fourteen trials involving 7376 children and 
      adults with AD were included. Calcineurin inhibitors were significantly more 
      effective than various potency TCS, neither least potent to lower mid-strength 
      nor mid-strength to potent TCS (RR = 1.24, 95% CI: 1.06-1.44). The major AEs were 
      skin burning and pruritus, their incidence was higher in TCI treatment (RR = 
      3.32, 95% CI: 2.90-3.80; RR = 1.59, 95% CI: 1.34-1.80). CONCLUSIONS: Calcineurin 
      inhibitors seem to be more effective and contrarily they elicit more AEs than 
      TCS.
CI  - Copyright (c) 2019 Termedia.
FAU - Abedz, Natalia
AU  - Abedz N
AD  - Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of 
      Sciences, Wroclaw, Poland.
FAU - Pawliczak, Rafal
AU  - Pawliczak R
AD  - Department of Immunopathology, Chair of Allergology, Immunology and Dermatology, 
      Medical University of Lodz, Lodz, Poland.
LA  - eng
PT  - Journal Article
DEP - 20191230
PL  - Poland
TA  - Postepy Dermatol Alergol
JT  - Postepy dermatologii i alergologii
JID - 101168357
PMC - PMC6986278
OTO - NOTNLM
OT  - atopic dermatitis
OT  - calcineurin inhibitors
OT  - corticosteroids
OT  - meta-analysis
OT  - tacrolimus
COIS- The authors declare no conflict of interest.
EDAT- 2020/01/31 06:00
MHDA- 2020/01/31 06:01
PMCR- 2019/12/01
CRDT- 2020/01/31 06:00
PHST- 2019/05/06 00:00 [received]
PHST- 2019/06/28 00:00 [accepted]
PHST- 2020/01/31 06:00 [entrez]
PHST- 2020/01/31 06:00 [pubmed]
PHST- 2020/01/31 06:01 [medline]
PHST- 2019/12/01 00:00 [pmc-release]
AID - 91425 [pii]
AID - 10.5114/ada.2019.91425 [doi]
PST - ppublish
SO  - Postepy Dermatol Alergol. 2019 Dec;36(6):752-759. doi: 10.5114/ada.2019.91425. 
      Epub 2019 Dec 30.